Compare Novartis AG (NVS) vs Rivian Automotive, Inc. (RIVN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Rivian Automotive, Inc. — how do they compare? Novartis AG trades at $142.74 (market cap $268.57B), while Rivian Automotive, Inc. trades at $14.27 (market cap $20.75B). The key difference: Novartis AG is far larger — about 12.9× Rivian Automotive, Inc.'s market cap, and Novartis AG pays a 3.31% dividend while Rivian Automotive, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novartis AG for 82 Days and Rivian Automotive, Inc. for 61 Days on average.
| NVS | RIVN | |
|---|---|---|
Market Cap | $268.57B | $20.75B |
Volume | 1,532,573 | 26,144,654 |
Sector | Health | Consumer Cyclical |
52-Week High | $168.62 | $22.45 |
52-Week Low | $121.80 | $12.50 |
Typical Hold Time | 82 Days | 61 Days |
Enterprise Value | $309.89B | $20.79B |
Dividend Yield | 3.31% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $143.28, up 1.77% today, with mixed technical signals showing neutral momentum. The company demonstrates strong fundamentals with $56.67B revenue in 2025, 22.5% net margin, and consistent earnings beats in recent quarters. Recent developments include a significant $7.8B licensing deal with China's Abogen for mRNA therapy, though offset by clinical trial setbacks in ALS drug development and ongoing investor scrutiny of M&A strategy.
Outlook remains cautiously optimistic with analyst consensus target of $146 suggesting modest upside. Key opportunities include pipeline expansion through strategic partnerships, while risks involve clinical trial failures, M&A integration challenges, and patent cliff pressures. The stock presents a balanced risk-reward profile with strong profitability offset by pipeline execution concerns.
Rivian Automotive (RIVN) trades at $14.34, down 1.17% on the day, reflecting a bearish technical outlook despite recent record Q3 2026 deliveries of 19,248 vehicles. The company continues to post significant net losses, with a -54.95% net income margin for 2025, though revenue growth is evident, rising to $5.39B. Analyst consensus is mixed, with a $16.89 price target, but cash burn remains a concern with negative operating cash flow.
The outlook hinges on R2 production scaling and future profitability; upside exists if Rivian achieves cost reductions and autonomy tech gains traction, but high cash burn, competitive pressures, and execution risks pose substantial threats to shareholder value in the near term.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Rivian Automotive, Inc.
Rivian Automotive, Inc. is an automotive technology company. The Company designs and manufactures vans, trucks, and sports utility vehicles, as well as offers repair and maintenance services. Rivian Automotive serves customers in North America and the United Kingdom.
Read more on RIVN →
